PTHS Pelthos Therapeutics Inc.: institutional ownership and insider trading
25 funds reported holding $39.7M of Pelthos Therapeutics Inc. in their latest 13F filings; in Q2 2026 funds net bought $11.6M, with 10 new positions and 3 funds selling out; over the last 12 months insiders bought $1000K and sold $486K on the open market; over its last four quarters it reported revenue of $43.3M and net income of −$86.4M.
PTHS revenue and earnings
- Quarter ended Jun 30, 2026: revenue $15.6M, net income −$23.4M, EPS -6.62
- Quarter ended Mar 31, 2026: revenue $10.9M, net income −$25.1M, EPS -7.57
- Quarter ended Dec 31, 2025: revenue $9.39M, net income −$21.7M, EPS -9.24
- Quarter ended Sep 30, 2025: revenue $7.41M, net income −$16.2M, EPS -5.30
Famous investors holding PTHS
- Ken Griffin (Citadel Advisors): $425K, 0.0% of the portfolio
Largest institutional holders of PTHS
- AIGH Capital Management LLC — $9.30M
- Murchinson Ltd. — $8.60M
- Ikarian Capital, LLC — $7.25M
- BOOTHBAY FUND MANAGEMENT, LLC — $2.88M
- VANGUARD CAPITAL MANAGEMENT LLC — $2.75M
- VANGUARD GROUP INC — $2.33M
- CANTOR FITZGERALD, L. P. — $1.08M
- J. Goldman & Co LP — $1.08M
- DIADEMA PARTNERS LP — $700K
- WEXFORD CAPITAL LP — $632K
Recent PTHS insider trades
- Oct 2, 2026: Pauls Matthew sold 786 shares ($16.5K)
- Oct 2, 2026: Friedberg Ezra M sold 558 shares ($11.6K)
- Oct 2, 2026: Greenleaf Peter sold 797 shares ($16.9K)
- Jul 2, 2026: Greenleaf Peter sold 797 shares ($20.8K)
5%+ owners
- 3i, LP: 9.9% (Schedule 13G/A, filed May 7, 2026)
- Ikarian Capital, LLC: 7.7% (Schedule 13G/A, filed May 15, 2026)